A Randomised, Double-blind, Multiple Period Crossover Trial Comparing Insulin 454 and Insulin Aspart Premixes With Separately Injected, Simultaneous Doses of Insulin 454 and Insulin Aspart, Compared With Biphasic Insulin Aspart 30 (NovoMix 30) in Male Subjects With Type 1 and Type 2 Diabetes Mellitus

Trial Profile

A Randomised, Double-blind, Multiple Period Crossover Trial Comparing Insulin 454 and Insulin Aspart Premixes With Separately Injected, Simultaneous Doses of Insulin 454 and Insulin Aspart, Compared With Biphasic Insulin Aspart 30 (NovoMix 30) in Male Subjects With Type 1 and Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2015

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin aspart/insulin protamine aspart (Primary) ; Insulin degludec (Primary) ; Insulin degludec/insulin aspart (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 20 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top